CN109161545A - Inhibit the microRNA of chicken Sirt1 gene expression and its recombinates table plasmid and LMH cell line - Google Patents

Inhibit the microRNA of chicken Sirt1 gene expression and its recombinates table plasmid and LMH cell line Download PDF

Info

Publication number
CN109161545A
CN109161545A CN201811118711.3A CN201811118711A CN109161545A CN 109161545 A CN109161545 A CN 109161545A CN 201811118711 A CN201811118711 A CN 201811118711A CN 109161545 A CN109161545 A CN 109161545A
Authority
CN
China
Prior art keywords
microrna
sirt1
sequence
plncx
chicken
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201811118711.3A
Other languages
Chinese (zh)
Other versions
CN109161545B (en
Inventor
郁建锋
顾志良
王中亮
陈迟迟
张燕萍
邵芳
徐璐
胡悦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Changshu Institute of Technology
Original Assignee
Changshu Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Changshu Institute of Technology filed Critical Changshu Institute of Technology
Priority to CN201811118711.3A priority Critical patent/CN109161545B/en
Publication of CN109161545A publication Critical patent/CN109161545A/en
Application granted granted Critical
Publication of CN109161545B publication Critical patent/CN109161545B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/78Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • C12N2310/141MicroRNAs, miRNAs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/10041Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

The invention discloses a kind of microRNA for inhibiting chicken Sirt1 gene expression, and disclose it and recombinated table plasmid and concrete application, and utilize the LMH cell line for being overexpressed miRNAs building stable low-expression Sirt1 gene.Compared with the existing technology, the present invention interferes target gene with the miRNA of engineer, and the over-express vector of the miRNA is directly quickly constructed by simple round pcr, pLNCX-pmirG provided by the present invention is the good carrier that miRNA is overexpressed, and it can successively carry out the packaging of retrovirus, it can be quickly obtained in conjunction with G418 pressurization screening and green fluorescent protein detection method and stablize the cell line for being overexpressed miRNA, Sirt1 gene can be not only disclosed for research influences liver to the acknowledgement mechanism of nutritional status, it also is the research mankind, it is model that function of the animal's liver in energetic supersession, which provides a unique liver cell subclone,.

Description

Inhibit the microRNA of chicken Sirt1 gene expression and its recombinates table plasmid and LMH Cell line
Technical field
The present invention relates to cell engineerings, in particular to inhibit the microRNA of chicken Sirt1 gene expression and its recombinated table Plasmid and LMH cell line.
Background technique
SIRT1 is as dependence NAD+Deacetylase, cell metabolism state (energy state) factor NAD+Make SIRT1 at For an important molecule for contacting energetic supersession and genetic transcription, SIRT1 passes through NAD+It is connected to gene in metaboilic level and core The response that the network of transcription regulates and controls and body makes nutrition, hormone and environmental stimulus.Liver is Animal nutrition substance and energy The important place of metabolism is measured, the synthesis of Glycogen synthesis, gluconeogenesis, fatty acid and cholesterol and the generation of lipoprotein are responsible for and is divided It secretes, and nutritional status and hormone signal can be made a response, the intracorporal substance of machine and energy balance are adjusted, especially in glycolipid class Metabolism aspect plays an important role.When body takes in excessive energy matter, liver can be by these excessive energy objects Matter is converted into fat, and is transported to adipose tissue and is stored up.Excessive energy is taken in for a long time eventually results in fat, fatty liver With other fat relevant metabolic diseases.In poultry production, fat deposition excessively not only influences the health of animal, can also draw The problems such as playing efficiency of feed utilization and laying rate decline.The fat of deposition is in addition to a small amount of fat in feed, mainly from liver The dirty fat recombined.Therefore, study liver fat metabolism and its regulatory mechanism for control poultry fat deposition pole It is important.The present invention not only can be to grind using the LMH cell line for being overexpressed miRNAs building stable low-expression Sirt1 gene Study carefully and disclose Sirt1 gene influence liver to the acknowledgement mechanism of nutritional status, is also the research mankind, animal's liver in energetic supersession Function to provide a unique liver cell subclone be model.
Summary of the invention
Goal of the invention: being directed to technology vacancy of the existing technology, and this application provides inhibit chicken Sirt1 gene expression MicroRNA and its table plasmid and LMH cell line were recombinated, and provides corresponding construction method and application.
Technical solution: a kind of microRNA inhibiting chicken Sirt1 gene expression of the present invention is named as GSmiR30, sequence is as shown in SEQ ID NO:1.
MicroRNA of the present invention by clone chicken Sirt1 gene 3 ' UTR sequences, then choose base sequence in Lower site is as target spot: " CAGCATTAGAAGCTTTGGCAT ", design obtains;3 ' UTR sequence such as SEQ of the chicken Sirt1 gene Shown in ID NO:2.
A kind of microRNA inhibiting chicken Sirt1 gene expression of the present invention, is named as gSmiR70, sequence is such as Shown in SEQ ID NO:3;Then the gSmiR70 is chosen in base sequence by 3 ' UTR sequences of clone's chicken Sirt1 gene The site " TCTGGATTTAGAGCAAGGAAA " is obtained as shot design;3 ' UTR sequences such as SEQ the ID of the chicken Sirt1 gene Shown in NO:2.
A kind of microRNA inhibiting chicken Sirt1 gene expression of the present invention, is named as gSmiR91, sequence is such as Shown in SEQ ID NO:4;Then the gSmiR91 is chosen in base sequence by 3 ' UTR sequences of clone's chicken Sirt1 gene The site " CCATAAGGATGTGGTGTTTAT " is obtained as shot design;3 ' UTR sequences such as SEQ the ID of the chicken Sirt1 gene Shown in NO:2.
MicroRNA of the present invention crosses the construction method of table retroviral vector, comprising the following steps: utilizes pLNHX The basic sequence and pcDNA of plasmidTMMicroRNA on 6.2-GW/EmGFP-miR plasmid expresses frame sequence construct pLNCX- PmiRG plasmid, design primer add insertion in the microRNA expression cassette of pLNCX-pmirG respectively using PCR amplification method GSmiR30/70/91 precursor DNA sequence obtains the plasmid for recombinating the microRNA of table: pLNCX-gSmiR30/70/91;Its In, the sequence of building gained pLNCX-pmiRG plasmid is as shown in SEQ ID NO:11.
Wherein, the pLNCX-gSmiR30 design primer gga-miR-SIRT1-30-F/R, sequence such as SEQ ID NO: Shown in 5-6;The pLNCX-gSmiR70 design primer gga-miR-SIRT1-70-F/R, sequence such as SEQ ID NO:7-8 institute Show;The pLNCX-gSmiR91 design primer gga-miR-SIRT1-91-F/R, sequence as shown in SEQ ID NO:9-10, See Table 1 for details:
1 PCR primer sequence of table
Building gained microRNA crosses table retroviral vector pLNCX-gSmiR30/70/91 also in protection of the invention In range.
The microRNA crosses table retroviral vector pLNCX-gSmiR30/70/91 and treats chicken Sirt1 base in preparation Because the application in abnormal expression related disease drug is also within the scope of the present invention.
A kind of LMH cell line of low expression Sirt1 gene of the present invention utilizes the above-mentioned microRNA structure of overexpression Build gained, comprising the following steps: after selecting the viral packaging of microRNA progress, infect LMH cell line;Then anti-using G418 Property pressurization screening and green fluorescent protein detection combine method screening obtain Sirt1 gene low expression LMH subcloned cells System.
Preferably, the concentration of the G418 pressurization screening is 1 μ g/mL, after screening 10 days, continues pressurization sieve after cell of transferring Choosing, repeat 3-5 times, finally using obtain egfp expression rate 98% or more cell as recombinant cell, and respectively from MRNA and protein expression level determine that the recombinant cell obtained is the LMH subclonal cell line of Sirt1 gene low expression.
The utility model has the advantages that compared with the existing technology, it is provided by the present invention that target gene is done with the miRNA of engineer It disturbs, and directly quickly constructs the over-express vector of the miRNA, pLNCX- provided by the present invention by simple round pcr PmirG is the good carrier that miRNA is overexpressed, and can successively carry out the packaging of retrovirus, in conjunction with G418 Pressurization screening and green fluorescent protein detection method can be quickly obtained cell line (the i.e. target gene quilt stablized and be overexpressed miRNA Stablize the cell line of interference).Its main advantage is: constructing stable low-expression Sirt1 gene using miRNAs is overexpressed LMH cell line, it is also research people that Sirt1 gene can be not only disclosed for research, which influences liver to the acknowledgement mechanism of nutritional status, It is model that the function of class, animal's liver in energetic supersession, which provides a unique liver cell subclone,.
Detailed description of the invention
Fig. 1 is the PCR and digestion result of miRNAs over-express vector, wherein the PCR of A:pLNCX-gSmiR30/70/91 As a result, B: the EcoR I digestion result of recombinant plasmid pLNCX-gSmiR30/70/91;M is DL5000 or DL10000;1,2,3 It is followed successively by pLNCX-gSmiR30/70/91;4,5,6 it is followed successively by pLNCX-gSmiR30/70/91 plasmid;
Fig. 2 is verifying of the miRNA to target spot function and effect, Control:pLNCX-pmirG;gSmiR30: pLNCX- gSmiR30;gSmiR70:pLNCX-gSmiR30;gSmiR91:pLNCX-gSmiR30;* indicates p < 0.01);
Fig. 3 is miRNAs interference LMH cell Sirt1 gene as a result, Control:pLNCX-pmirG; gSmiR30: pLNCX-gSmiR30;2:gSmiR70:pLNCX-gSmiR30;GSmiR91:pLNCX-gSmiR30, * indicate p < 0.05;
Fig. 4 is the expression of results of GFP in LMH-gSmiR30 cell line, GFP in fluorescence microscope LMH-gSmiR30 Expression, A figure: light field (200 ×);B figure: dark field (200 ×);
Fig. 5 is the mRNA expression of Sirt1 gene in LMH-gSmiR30 cell line, LMH-pmirG: control;LMH- GSmiR30:SIRT1 gene low expression cell line, * * indicate p < 0.01;
Fig. 6 is the expression of SIRT1 albumen in LMH-gSmiR30 cell line;
Fig. 7 is the Western blot testing result that total protein of cell is extracted with Western/IP lysate, with β-Actin As internal reference, 1:LMH-pmirG (Control);2:LMH-gSmiR30 is (for constructed Sirt1 gene low expression cell System).
Specific embodiment
The application is explained in detail combined with specific embodiments below.
Cell and plasmid origin: LMH cell is purchased from ATCC;PLNHX plasmid is purchased from Clontech; pcDNATM6.2-GW/ EmGFP-miR plasmid is purchased from Invitrogen.
Instrument and equipment:
Embodiment 1 inhibits the design of the microRNAs of chicken Sirt1 gene expression
3 ' the UTR sequences for cloning chicken Sirt1 gene obtained are inputted into Designed microRNA (the BLOCK- iTTMRNAi Designer) on-line analysis tool (http://rnaidesigner.thermofisher.com/ Rnaiexpress/setOption.do? designOption=mirna &pid=-3453238029932242172), target position Point area is selected as " 3 ' UTR ";Option of species chicken, G/C content are selected as 35%-55%.3 different locis of picking, comment Divide 3 best miR RNAi, is respectively as follows: gSmiR30: " 5 ' AUGCCAAAGCUUCUAAUGCUG3 ' ";GSmiR70: " UUUCCUUGCUCUAAAUCCAGA " and gSmiR91: " AUAAACACCACAUCCUUAUGG ".
The building of embodiment 2miRNAs over-express vector
Utilize the basic sequence and pcDNA of pLNHX plasmidTMMicroRNA expression on 6.2-GW/EmGFP-miR plasmid Frame sequence is by pcDNATMSequence between 17-1919 on 6.2-GW plasmid (includes CMV promoter, the site attB1, EmGFP The miR flanking sequence of gene order, 5 ' and 3 ', the site attB2 and TK polyadenosine acid signal) replace 2047- on pLNHX plasmid The segment (including HSP70 promoter and multiple cloning sites) in 2370 area, successfully constructs pLNCX-pmiRG plasmid, sequence is such as Shown in SEQ ID NO:11.
According to the microRNA design primer of design, using PCR amplification method respectively in the microRNA of pLNCX-pmirG The microRNA precursor DNA sequence that expression cassette addition insertion embodiment 1 designs, obtains the plasmid for recombinating the microRNA of table: pLNCX-gSmiR30、pLNCX-gSmiR70、 pLNCX-gSmiR91。
Method is as follows:
The plasmid for recombinating the microRNA of table is obtained using plasmid pLNCX-pmiG: pLNCX-pmiG plasmid divides as template Not Yong gga-miR-SIRT1-30-F/R, gga-miR-SIRT1-70-F/R, gga-miR-SIRT1-91-F/R tri- to primer expand Increase overall length plasmid sequence, be tapped and recovered DNA purpose band, then carries out 5 ' end phosphorylations, it is certainly a chain of finally by segment Change, secondary connection product is transferred in DH5 α Escherichia coli, prepares the plasmid for obtaining the microRNA for recombinating table: pLNCX- gSmiR30, pLNCX-gSmiR70,pLNCX-gSmiR91.Step:
(1) PCR reacts
Reaction system:
Reaction condition:
(2) 0.8% agarose gel electrophoresis detects, and is tapped and recovered target fragment;
(3) recycling segment 5 ' holds phosphatizing treatment:
System:
Reaction condition: 37 DEG C of 30min, 70 DEG C of 10min.
(4) product (3) is directly taken, self connection reaction is carried out:
(5) connection product is transformed into competent cell DH5 α, Amp resistance screening, the amplification of picking resistance positive bacterium colony After culture, plasmid is extracted, is identified with EcoR I digestion, positive plasmid send sequencing to identify.Sequencing is correctly constructed mistake Express the plasmid of microRNA: pLNCX-gSmiR30, pLNCX-gSmiR70, pLNCX-gSmiR91.
The PCR result and digestion result of building gained miRNAs over-express vector are as shown in Figure 1, wherein A:pLNCX- The PCR of gSmiR30/70/91 is as a result, B: (M is for the EcoR I digestion result of recombinant plasmid pLNCX-gSmiR30/70/91 DL5000 or DL10000;1,2,3 it is followed successively by pLNCX-gSmiR30/70/91;4,5,6 it is followed successively by pLNCX-gSmiR30/70/ 91 plasmids).By Fig. 1-A as it can be seen that using pLNCX plasmid as template, primer gga-miR-SIRT1-30-F/R, gga- are used respectively MiR-SIRT1-70-F/R, gga-miR-SIRT1-91-F/R carry out PCR amplification and obtain the piece greater than 5000bp (about 7000bp) Section, this is consistent with the theoretical value of segment of design amplification, and illustration purpose fragment amplification success, this 3 bar segment is cyclized through self After be transformed into DH5 α, the bacterium colony culture of the picking Amp resistance positive, and extract plasmid.By Fig. 1-B as it can be seen that institute's upgrading grain passes through 7000bp or so DNA fragmentation is respectively obtained after EcoR I digestion, it is consistent with the theoretical value of design, illustrate to connect and be converted to Then function send the clone of the digestion positive to sequencing respectively.
3 miRNAs effect test of embodiment
1, the 3 ' UTR sequence of chicken Sirt1 gene cloned according to this laboratory, with ggaSIRT1-UTR672-F (ATCTCGAGAGTGCTCACTGGTTACAGG)/ggaSIRT1-UTR672-R (ATGCGGCCGCAAGCTCAGTAACTGAAGC), expand that obtain include 3 from the genome of chicken by round pcr 3 ' the UTR sequence of Sirt1 gene of miRNAs (gSmiR30,70 and 91) target site point, and be cloned into pSicheck2 3 ' the area UTR of Synthetic Renilla luciferase gene (hRluc) gene obtains Dual-Luciferase report carrier pSicheck2-gSirt1-UTR672.Steps are as follows:
(1) phenol imitates the genome that method extracts chicken red blood cell;
(2) PCR amplification target fragment (gSirt1-UTR672):
Reaction system:
Reaction condition:
(3) target fragment is recycled after 1% agarose gel electrophoresis, digest recycling segment and report respectively with Xho I and Not I Accuse carrier pSicheck2 plasmid;
(4) it is tapped and recovered target fragment after agarose electrophoresis, then connects the two, is transformed into DH5 α, and PCR and digestion Identification extracts positive plasmid and send sequencing, obtains building correctly recombination report carrier pSicheck2-gSirt1-UTR672.
Construct the PCR and digestion qualification result such as Fig. 2, M:DL5000 of report carrier psiCHECH2-gSirt1-UTR672 Or DL10000;The amplification of 1:gSirt1-UTR672 segment;2: recombination reporter plasmid psiCHECH2-gSirt1-UTR672 Not I and Xho I double digestion result.By Fig. 2-A as it can be seen that with chicken genomic DNA template, with primer ggaSIRT1-UTR672- F/R, Successful amplification obtain the segment for being about 700bp, in the same size with estimated amplification.Fig. 2-B result explanation, target fragment success 3 ' UTR of Renilla luciferase gene (hRluc) gene are inserted into, positive plasmid is taken to be sequenced, it is correct to obtain building Report carrier psiCHECH2-gSirt1-UTR672.
2, the overexpression of 3 miRNAs of cotransfection the effect identification of miRNAs action target spot: is distinguished in CHO-K1 cell line Carrier pLNCX-gSmiR30/70/91 and report carrier pSicheck2- containing the 3 ' area UTR target site sequence of Sirt1 gene The activity of luciferase is detected after gSirt1-UTR672,48h to verify 3 miRNAs effects of effect.Steps are as follows:
(1), with F12K (containing 10% fetal calf serum, 1% is dual anti-) recovery culture CHO-K1, convergence degree is grown to 90% to it Passage cell, by 1.2 × 105The cell concentration of/mL is laid in 24 well culture plates (hole 0.5mL/), and 37 DEG C of 5%CO2 cultivate 22h, more Not antibiotic F12K complete medium is changed, continues to cultivate 2h;
(2) cotransfection, prepare 32 μ L of transfection cocktail OptiMEM (viral expression plasmids pLNCX-gSmiR30 350ng and Report carrier plasmid pSicheck2-gSirt1-UTR672 50ng;X-tremeGENE 9DNA Transfection 1.2 μ L of Reagent), room temperature acts on 20min after mixing, mix, after 21 DEG C of standing 20min, mixed liquor be added dropwise to cell Continue to cultivate 48h in culture medium, after mixing;
(3) luciferase detection (Dual-Luciferase Reporter Assay System Kit), the method is as follows:
1. taking 24 well culture plates, culture medium is abandoned, the PBS that 37 DEG C of 1mL preheatings are added washed once;
2. detection process is carried out referring to Dual-Luciferase Reporter Assay System Kit specification;
3. calculating renilla luciferase activity and firefly luciferase activity ratio, that is, relative luciferase activity.
(4) in LMH cell, it is effective that verifying is transiently transfected with X-tremeGENE 9DNA Transfection Reagent 3 miRNAs over-express vectors pLNCX-gSmiR30/70/91,48h after fluorogenic quantitative detection Sirt1 gene mRNA water It is flat.
As seen from Figure 3,3 miRNAs can effectively inhibit renilla luciferase activity (inhibit efficiency reach 97% with On), illustrate that 3 designed miRNAs can may be expressed after the transcription by corresponding target site participation chicken Sirt1 gene Regulation.From fig. 4, it can be seen that being instantaneously overexpressed this 3 miRNAs, the mRNA level in-site of the Sirt1 gene in LMH cell is inhibited by 30% or so, further illustrate that these three 3 miRNAs can interfere the expression of Sirt1 gene from mRNA level in-site.
Embodiment 4 constructs the LMH subclonal cell line that recombinant cell is Sirt1 gene low expression
After selecting the viral packaging of gSmiR30 progress, LMH cell line is infected, constructs sub- gram of LMH of Sirt1 gene low expression Grand cell line.Method is as follows:
(1), with DMEM complete medium (containing 10% fetal calf serum, 1% is dual anti-) culture GP2-293 cell line, grown extremely to it Cell passage is carried out when 90% or more convergence degree, by 5 × 105The cell concentration of/mL is inoculated in the culture dish (culture medium of 10cm For 10mL), 37 DEG C of 5%CO2After cultivating 22h, the DMEM complete medium of antibiotic-free is changed into, continue to cultivate 2h;
(2) 500 μ L of transfection cocktail OptiMEM (pLNCX-gSmiR30 containing viral expression plasmids and packaging auxiliary matter are prepared Each 2.5 μ g of grain pVSV-G;15 μ L of X-tremeGENE 9DNA Transfection Reagent), room temperature acts on after mixing Then 20min is dropped evenly into culture dish, 37 DEG C of 5%CO2Cultivate 72h;
(3) 4 DEG C of 500 × g are centrifuged 10min, collect supernatant, -80 DEG C are frozen after packing to get virion.
(4) LMH cell presses 3 × 105/ hole is inoculated in 12 well culture plates, the Waymouth ' s complete medium in the hole 1mL/, 37 DEG C of 5%CO2Not antibiotic Waymouth ' s complete medium is changed after culture 22h, continues to cultivate 2h;
(5) virus of collection pack after supernatant doubling dilution and polybrene mixing with the culture of the basis Waymouth ' s, to 0.5mL infection liquid (1/2 volume of culture medium) is added dropwise in cell culture medium, the final concentration of polybrene≤4 μ g/mL mixes;
(6) culture plate is placed in 32 DEG C, 1,200 × g is centrifuged 90min (improve efficiency of infection), then 37 DEG C of 5% CO2 18h is cultivated, fresh Waymouth ' s complete medium is replaced, removes polybrene;
(7) after continuing culture for 24 hours, G418 being added to final concentration 1 μ g/mL, daily 3d and changes liquid, the resistance for carrying out G418 continues (concentration of G418 pressurization screening is 1 μ g/mL, after screening 10 days, continues pressurization sieve after cell of transferring for sieve and subcloning culture Choosing repeats 3-5 times), screen recombinant cell;
(8) recombinant cell LMH-pLNCX-pmirG (LMH-pmirG) and LMH-pLNCX-gSmiR30 (LMH- are obtained GSmiR30) after (ratio of cell expressing green fluorescent protein is 98% or more), with the G418's containing 100ng/mL Waymouth ' s complete medium carries out secondary culture.
(9) recombinant cell is collected, total serum IgE and total protein is extracted, is carried out respectively with fluorescent quantitation and Western Blot The detection of Sirt1 gene mRNA and protein expression level.
It is pressurizeed using G418 resistance and screens table low with the method screening acquisition Sirt1 gene that green fluorescent protein detection combines The LMH subclonal cell line reached can be seen that from Fig. 5 result through the duplicate screening of multiple G418, the cell finally obtained it is glimmering The expression rate of photoprotein has reached 98% or more, illustrates that cell obtained has all successfully been transferred to fluorescent marker protein.From Fig. 6 Can be seen that in screened recombinant cell Sirt1 with the result of Fig. 7 is all had in mRNA and protein expression level The inhibition of effect illustrates that Sirt1 gene is stablized the LMH subclonal cell line of the recombinant cell LMH-gSmiR30 of low table and constructed successfully.
Sequence table
<110>Changshu Institute of Technology
<120>inhibit the microRNA of chicken Sirt1 gene expression and its recombinate table plasmid and LMH cell line
<160> 11
<170> SIPOSequenceListing 1.0
<210> 1
<211> 21
<212> RNA
<213>artificial sequence (Artificial Sequence)
<400> 1
augccaaagc uucuaaugcu g 21
<210> 2
<211> 1710
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 2
agtgctcact ggttacagga attttccacc agcattagaa gctttggcat gtcaggaaga 60
atgtttacgt ctggatttag agcaaggaaa ccataaggat gtggtgttta taagcaactg 120
aaacagattt tcatgcttag ttttttacct ttttcaataa aattctctta ctgcacactc 180
aacactaact ttttttttta aggtactagg aatatctaag caattattac tatgttcact 240
tttaagtcat ctgtctgatc aggcatccat gtatataata cctattttgc ataataaatt 300
tcagcttata ttatttttaa acagttttga aaaagccatt ggaatgttaa actaatataa 360
agggaacagc taatttaaac caaaaaaggg tattatcaca cttcttgctt tgtaacagtt 420
tggtttattt aaaacttctt acgcttctgc taaaccttta gttctcgcat agcctatcat 480
taaacactgg cattttctaa gacctactgt ggcagctaat tttttgcttt aacaattagt 540
ttgtatgttt gagacatact taaatgtgag tagatagtta aaaatggaaa caagacagta 600
agcacttgaa aactcctaat cttttttaga ctgataagaa gtgctgtgaa aatgcttcag 660
ttactgagct taatacttcc tgtggacatg aagcaatgtt gacattggct ccttagcaat 720
tataatactg gaacgtcagt attttaggca aaatggattc ccaatggcag aagtttttca 780
cattgtatac aagaagtcaa atatagtgca gcttgcatta acaatagtat tcgatcaatt 840
gccaaggctg taacatggag gcttggctga gtacacaaca gcgttcctac cagcatgtga 900
gaaggcacgg aaaccaaatc tcttcctgta atgcttacgg aagtaacaga atcagaagaa 960
acttgctcag agagcaacag cctctgctgc tactgctgtg tgggtgaaat acagattcat 1020
cacctgctgc ttcgagtgat gtcccagacg gggaacgtga ctttccaccc gctagctcca 1080
acgtgcatct tagaagcaaa gcagctactc caattatcac attgcgtatt aaagtgctaa 1140
gctgccttaa aactggatgt tgcaaacttt caagtgcaga ttgtttccaa gcctttagaa 1200
ttattttgta aaattgtaca gtgcagtagt aagtgaatca gcatttttta tataaaccac 1260
tttttcaaca ttggcccaaa tgaactctac ggtgtagatt attcatatcc tttgctttaa 1320
tatttattac attttggaga tgtatagtag ctgttctttg aaggtaagat acatcactta 1380
atgaatattt aagaacagtt ttctgtattc atctaaaaat gttggcatgt tgtctcattg 1440
tccaaattta atacagctct tatttggcta cactaaagaa tgcaatatgt ttagttttca 1500
cttgcatgtt acaatgtatt agtttgtgct ataggagata ttttaaattg aaatactttg 1560
ttttaaaata tttttacagt gaggattgtt ttctgctctt ttatattgta tatagtgtct 1620
tttatgtaat ctactggcat atgttttgta gaagactgtt taaaatgacc ggctatcttc 1680
ctgcaacttt tgaaatacaa aaaaaaaaaa 1710
<210> 3
<211> 21
<212> RNA
<213>artificial sequence (Artificial Sequence)
<400> 3
uuuccuugcu cuaaauccag a 21
<210> 4
<211> 21
<212> RNA
<213>artificial sequence (Artificial Sequence)
<400> 4
auaaacacca cauccuuaug g 21
<210> 5
<211> 56
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 5
cactgactga ccagcattaa gctttggcat caggacacaa ggcctgttac tagcac 56
<210> 6
<211> 56
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 6
gccaaaacca gcattagaag ctttggcatc agcatacagc cttcagcaag cctcca 56
<210> 7
<211> 56
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 7
cactgactga ctctggattg agcaaggaaa caggacacaa ggcctgttac tagcac 56
<210> 8
<211> 56
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 8
gccaaaactc tggatttaga gcaaggaaac agcatacagc cttcagcaag cctcca 56
<210> 9
<211> 56
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 9
cactgactga cccataaggg tggtgtttat caggacacaa ggcctgttac tagcac 56
<210> 10
<211> 56
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 10
gccaaaaccc ataaggatgt ggtgtttatc agcatacagc cttcagcaag cctcca 56
<210> 11
<211> 7278
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 11
agcaaagaaa cggaagggcc gcggctttgg ctccggtgag tgtggggaat agggtagagt 60
ggtctaagag gcagaagccc gcgaatttgg gagtgtgagg gggacacatt tggaggacag 120
ttttcggtga tctggtatga attcttgaag acgaaagggc ctcgtgatac gcctattttt 180
ataggttaat gtcatgataa taatggtttc ttagacgtca ggtggcactt ttcggggaaa 240
tgtgcgcgga acccctattt gtttattttt ctaaatacat tcaaatatgt atccgctcat 300
gagacaataa ccctgataaa tgcttcaata atattgaaaa aggaagagta tgagtattca 360
acatttccgt gtcgccctta ttcccttttt tgcggcattt tgccttcctg tttttgctca 420
cccagaaacg ctggtgaaag taaaagatgc tgaagatcag ttgggtgcac gagtgggtta 480
catcgaactg gatctcaaca gcggtaagat ccttgagagt tttcgccccg aagaacgttt 540
tccaatgatg agcactttta aagttctgct atgtggcgcg gtattatccc gtgttgacgc 600
cgggcaagag caactcggtc gccgcataca ctattctcag aatgacttgg ttgagtactc 660
accagtcaca gaaaagcatc ttacggatgg catgacagta agagaattat gcagtgctgc 720
cataaccatg agtgataaca ctgcggccaa cttacttctg acaacgatcg gaggaccgaa 780
ggagctaacc gcttttttgc acaacatggg ggatcatgta actcgccttg atcgttggga 840
accggagctg aatgaagcca taccaaacga cgagcgtgac accacgatgc ctgcagcaat 900
ggcaacaacg ttgcgcaaac tattaactgg cgaactactt actctagctt cccggcaaca 960
attaatagac tggatggagg cggataaagt tgcaggacca cttctgcgct cggcccttcc 1020
ggctggctgg tttattgctg ataaatctgg agccggtgag cgtgggtctc gcggtatcat 1080
tgcagcactg gggccagatg gtaagccctc ccgtatcgta gttatctaca cgacggggag 1140
tcaggcaact atggatgaac gaaatagaca gatcgctgag ataggtgcct cactgattaa 1200
gcattggtaa ctgtcagacc aagtttactc atatatactt tagattgatt taaaacttca 1260
tttttaattt aaaaggatct aggtgaagat cctttttgat aatctcatga ccaaaatccc 1320
ttaacgtgag ttttcgttcc actgagcgtc agaccccgta gaaaagatca aaggatcttc 1380
ttgagatcct ttttttctgc gcgtaatctg ctgcttgcaa acaaaaaaac caccgctacc 1440
agcggtggtt tgtttgccgg atcaagagct accaactctt tttccgaagg taactggctt 1500
cagcagagcg cagataccaa atactgtcct tctagtgtag ccgtagttag gccaccactt 1560
caagaactct gtagcaccgc ctacatacct cgctctgcta atcctgttac cagtggctgc 1620
tgccagtggc gataagtcgt gtcttaccgg gttggactca agacgatagt taccggataa 1680
ggcgcagcgg tcgggctgaa cggggggttc gtgcacacag cccagcttgg agcgaacgac 1740
ctacaccgaa ctgagatacc tacagcgtga gctatgagaa agcgccacgc ttcccgaagg 1800
gagaaaggcg gacaggtatc cggtaagcgg cagggtcgga acaggagagc gcacgaggga 1860
gcttccaggg ggaaacgcct ggtatcttta tagtcctgtc gggtttcgcc acctctgact 1920
tgagcgtcga tttttgtgat gctcgtcagg ggggcggagc ctatggaaaa acgccagcaa 1980
cgcggccttt ttacggttcc tggccttttg ctggcctttt gctcacatgt tctttcctgc 2040
gttatcccct gattctgtgg ataaccgtat taccgccttt gagtgagctg ataccgctcg 2100
ccgcagccga acgaccgagc gcagcgagtc agtgagcgag gaagcggaag agcgcctgat 2160
gcggtatttt ctccttacgc atctgtgcgg tatttcacac cgcatatggt gcactctcag 2220
tacaatctgc tctgatgccg catagttaag ccagtataca ctccgctatc gctacgtgac 2280
tgggtcatgg ctgcgccccg acacccgcca acacccgctg acgcgccctg acgggcttgt 2340
ctgctcccgg catccgctta cagacaagct gtgaccgtct ccgggagctg catgtgtcag 2400
aggttttcac cgtcatcacc gaaacgcgcg aggcagccag cttacctccc ggtggtgggt 2460
cggtggtccc tgggcagggg tctcccgatc ccggacgagc ccccaaatga aagacccccg 2520
ctgacgggta gtcaatcact cagaggagac cctcccaagg aacagcgaga ccacaagtcg 2580
gatgcaactg caagagggtt tattggatac acgggtaccc gggcgactca gtcaatcgga 2640
ggactggcgc cccgagtgag gggttgtggg ctcttttatt gagctcgggg agcagaagcg 2700
cgcgaacaga agcgagaagc gaactgattg gttagttcaa ataaggcaca gggtcatttc 2760
aggtccttgg ggcaccctgg aaacatctga tggttctcta gaaactgctg agggctggac 2820
cgcatctggg gaccatctgt tcttggccct gagccggggc aggaactgct taccacagat 2880
atcctgtttg gcccatattc agctgttcca tctgttcttg gccctgagcc ggggcaggaa 2940
ctgcttacca cagatatcct gtttggccca tattcagctg ttccatctgt tcctgacctt 3000
gatctgaact tctctattct cagttatgta tttttccatg ccttgcaaaa tggcgttact 3060
taagctagct tgccaaacct acaggtgggg tctttcattc cccccttttt ctggagacta 3120
aataaaatct tttattttat ctatggctcg tactctatag gcttcagctg gtgatattgt 3180
tgagtcaaaa ctagagcctg gaccactgat atcctgtctt taacaaattg gactaatcga 3240
tgctatggca gggcctgccg ccccgacgtt ggctgcgagc cctgggcctt cacccgaact 3300
tggggggtgg ggtggggaaa aggaagaaac gcgggcgtat tggccccaat ggggtcacgg 3360
tggggtatcg acagagtgcc agccctggga ccgaaccccg cgtttatgaa caaacgaccc 3420
aacacccgtg cgttttattc tgtcttttta ttgccgtcat agcgcgggtt ccttccggta 3480
ttgtctcctt ccgtgtttca gttagcctcc cccatcagcg aaccgcgggc cctctagatc 3540
aaccactttg tacaagaaag ctgggtctag atatctcgag tgcggccaga tctgggccat 3600
ttgttccatg tgagtgctag taacaggcct tgtgtcctgc tttttgcggt cggcttgctg 3660
tcagtcagtg gccaaaacag caagcccaga ccgcaaaaag cagcatacag ccttcagcaa 3720
gcctccagga tccactggtc gactcactac ctccctttaa acgatcgacg gccacgaagt 3780
gcttagctta cttgtacagc tcgtccatgc cgagagtgat cccggcggcg gtcacgaact 3840
ccagcaggac catgtgatcg cgcttctcgt tggggtcttt gctcagggcg gactgggtgc 3900
tcaggtagtg gttgtcgggc agcagcacgg ggccgtcgcc gatgggggtg ttctgctggt 3960
agtggtcggc gagctgcacg ctgccgtcct cgatgttgtg gcgggtcttg aagttcacct 4020
tgatgccgtt cttctgcttg tcggcggtga tatagacctt gtggctgttg tagttgtact 4080
ccagcttgtg ccccaggatg ttgccgtcct ccttgaagtc gatgcccttc agctcgatgc 4140
ggttcaccag ggtgtcgccc tcgaacttca cctcggcgcg ggtcttgtag ttgccgtcgt 4200
ccttgaagaa gatggtgcgc tcctggacgt agccttcggg catggcggac ttgaagaagt 4260
cgtgctgctt catgtggtcg gggtagcggg cgaagcactg cacgccgtag gtgaaggtgg 4320
tcacgagggt gggccagggc acgggcagct tgccggtggt gcagatgaac ttcagggtca 4380
gcttgccgta ggtggcatcg ccctcgccct cgccggacac gctgaacttg tggccgttta 4440
cgtcgccgtc cagctcgacc aggatgggca ccaccccggt gaacagctcc tcgcccttgc 4500
tcaccatggt tttaaagcct gcttttttgt acaaacttgt tgatagctta actagccagc 4560
ttgggactcc ctatagtgag tcgtattaat ttcgataagc cagtaagcag tgggttctct 4620
agttagttaa cgatctgatc tgacggttca ctaaaccagc tctgcttata tagacctccc 4680
accgtacacg cctaccgccc atttgcgtca atggggcgga gttgttacga cattttggaa 4740
agtcccgttg attttggtgc caaaacaaac tcccattgac gtcaatgggg tggagacttg 4800
gaaatccccg tgagtcaaac cgctatccac gcccattgat gtactgccaa aaccgcatca 4860
ccatggtaat agcgatgact aatacgtaga tgtactgcca agtaggaaag tcccataagg 4920
tcatgtactg ggcataatgc caggcgggcc atttaccgtc attgacgtca atagggggcg 4980
tacttggcat atgatacact tgatgtactg ccaagtgggc agtttaccgt aaatactcca 5040
cccattgacg tcaatggaaa gtccctattg gcgttactat gggaacatac gtcattattg 5100
acgtcaatgg gcgggggtcg ttgggcggtc agccaggcgg gccatttacc gtaagttatg 5160
taacgcggaa ctccatatat gggctatgaa ctaatgaccc cgtaattgat tactattaat 5220
aactagtcga ggggatcgag cccggggtgg gcgaagaact ccagcatgag atccccgcgc 5280
tggaggatca tccagccggc gtcccggaaa acgattccga agcccaacct ttcatagaag 5340
gcggcggtgg aatcgaaatc tcgtgatggc aggttgggcg tcgcttggtc ggtcatttcg 5400
aaccccagag tcccgctcag aagaactcgt caagaaggcg atagaaggcg atgcgctgcg 5460
aatcgggagc ggcgataccg taaagcacga ggaagcggtc agcccattcg ccgccaagct 5520
cttcagcaat atcacgggta gccaacgcta tgtcctgata gcggtccgcc acacccagcc 5580
ggccacagtc gatgaatcca gaaaagcggc cattttccac catgatattc ggcaagcagg 5640
catcgccatg ggtcacgacg agatcctcgc cgtcgggcat gcgcgccttg agcctggcga 5700
acagttcggc tggcgcgagc ccctgatgct cttcgtccag atcatcctga tcgacaagac 5760
cggcttccat ccgagtacgt gctcgctcga tgcgatgttt cgcttggtgg tcgaatgggc 5820
aggtagccgg atcaagcgta tgcagccgcc gcattgcatc agccatgatg gatactttct 5880
cggcaggagc aaggtgagat gacaggagat cctgccccgg cacttcgccc aatagcagcc 5940
agtcccttcc cgcttcagtg acaacgtcga gcacagctgc gcaaggaacg cccgtcgtgg 6000
ccagccacga tagccgcgct gcctcgtcct gcagttcatt cagggcaccg gacaggtcgg 6060
tcttgacaaa aagaaccggg cgcccctgcg ctgacagccg gaacacggcg gcatcagagc 6120
agccgattgt ctgttgtgcc cagtcatagc cgaatagcct ctccacccaa gcggccggag 6180
aacctgcgtg caatccatct tgttcaatca tgcgaaacga tcctcatcct gtctcttgat 6240
cagatcggaa aacagcttta actaatccta ggctgagatg gatctattgg ctgcagcaga 6300
caagacgcgc ggcttcggtt ccaaaccgaa agcaaaaatt cagacggagg cgggaactgt 6360
tttaggttct cgtctcctac cagaaccaca tatcctgacg gggtcggatt ccacatcgac 6420
tcccttcctc aggtcgggcc acaaaaacgg cccccaaagt ccctgggacg tctcccaggg 6480
ttgcggccgg gtgttcagaa ctcgtcagtt ccaccacggg tccgccagat acagagctag 6540
ttagctaact agtacagacg caggcgcata acatcaaaca tagacactag acaatcggac 6600
agacacagat aagttgctgg ccagcttacc tcccggtggt gggtcggtgg tccctgggca 6660
ggggtctcca aatcccggac gagcccccaa atgaaagacc cccgtcgtgg gtagtcaatc 6720
actcagagga gaccctccca aggaacagcg agaccacgat tcggatgcaa acagcaagag 6780
gctttattgg gaatacgggt acccgggcga cgcagtctat cggaagactg gcgcgccgag 6840
tgaggggttg tgggctcttt tattgagctc ggagagcgga agcgcgcgaa cagaagcgag 6900
aagcgaactg attggttagt tcaaataagg tacagggtca ttttcaggtc cttggggcac 6960
cctggaaaca tctgatgatt cactagaaac tgctgagggc tggaccgcat ctggggacca 7020
tctgttcttg gccccgagcc ggggcaggaa ctgcttacca cagatatcct gtttggccca 7080
tcactcagct gtctcatctg ttcttggccc tgagccgggg caggaaccgc ttaccacaga 7140
tatcctgttt ggtattcagc tgtttctttg ttcctgacct tgatctgaac ttttctattc 7200
tcagttatgt atttttccat gccttgcaaa gtggcgttac ttaagctagc ttgccaccta 7260
cgggtggggt ctttcaaa 7278

Claims (10)

1. a kind of microRNA for inhibiting chicken Sirt1 gene expression, is named as gSmiR30, sequence such as SEQ ID NO:1 institute Show.
2. the microRNA according to claim 1 for inhibiting chicken Sirt1 gene expression, which is characterized in that the gSmiR30 By cloning 3 ' UTR sequences of chicken Sirt1 gene, site " CAGCATTAGAAGCTTTGGCAT " in base sequence is then chosen It is obtained as shot design.
3. a kind of microRNA for inhibiting chicken Sirt1 gene expression, is named as gSmiR70, sequence such as SEQ ID NO:3 institute Show;Then the gSmiR70 is chosen in base sequence by 3 ' UTR sequences of clone's chicken Sirt1 gene The site " TCTGGATTTAGAGCAAGGAAA " is obtained as shot design.
4. a kind of microRNA for inhibiting chicken Sirt1 gene expression, is named as gSmiR91, sequence such as SEQ ID NO:4 institute Show;Then the gSmiR91 is chosen in base sequence by 3 ' UTR sequences of clone's chicken Sirt1 gene The site " CCATAAGGATGTGGTGTTTAT " is obtained as shot design.
5. any microRNA crosses the construction method of table retroviral vector in a kind of claim 1-4, feature exists In, comprising the following steps: utilize the basic sequence and fpcDNA of pLNHX plasmidTMOn 6.2-GW/EmGFP-miR plasmid MicroRNA expresses frame sequence construct pLNCX-pmiRG plasmid, design primer, using PCR amplification method respectively in pLNCX- The microRNA expression cassette addition insertion expression gSmiR30/70/91 precursor DNA sequence of pmirG, acquisition recombinated table The plasmid of microRNA: pLNCX-gSmiR30/70/91.
6. construction method according to claim 5, which is characterized in that the pLNCX-gSmiR30 design primer is gga- MiR-SIRT1-30-F/R, sequence is as shown in SEQ ID NO:5-6;The pLNCX-gSmiR70 design primer gga-miR- SIRT1-70-F/R, sequence is as shown in SEQ ID NO:7-8;The pLNCX-gSmiR91 design primer gga-miR-SIRT1- 91-F/R, sequence is as shown in SEQ ID NO:9-10.
7. the building gained of claim 5 or 6 microRNA crosses table retroviral vector.
8. microRNA described in claim 7, which crosses table retroviral vector, treats chicken Sirt1 abnormal gene expression phase in preparation Application in related disorders drug.
9. a kind of LMH cell line of low expression Sirt1 gene, which is characterized in that utilize any institute in overexpression claim 1-4 State microRNA building, comprising the following steps: after selecting the viral packaging of microRNA progress described in claim 1, infect LMH Cell line;Then Sirt1 gene is obtained using the method screening that G418 resistance pressurization screening and green fluorescent protein detection combine The LMH subclonal cell line of low expression.
10. the LMH cell line of low expression Sirt1 gene according to claim 9, which is characterized in that the G418 pressurization The concentration of screening is 1 μ g/mL, after screening 10 days, continues pressurization screening after cell of transferring, repeats 3-5 times, finally to obtain green Fluorescent protein expression rate is recombinant cell in 98% or more cell.
CN201811118711.3A 2018-09-26 2018-09-26 microRNA for inhibiting expression of Sirt1 gene of chicken, recombinant superficies plasmid thereof and LMH cell line Active CN109161545B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811118711.3A CN109161545B (en) 2018-09-26 2018-09-26 microRNA for inhibiting expression of Sirt1 gene of chicken, recombinant superficies plasmid thereof and LMH cell line

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811118711.3A CN109161545B (en) 2018-09-26 2018-09-26 microRNA for inhibiting expression of Sirt1 gene of chicken, recombinant superficies plasmid thereof and LMH cell line

Publications (2)

Publication Number Publication Date
CN109161545A true CN109161545A (en) 2019-01-08
CN109161545B CN109161545B (en) 2021-07-27

Family

ID=64880539

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811118711.3A Active CN109161545B (en) 2018-09-26 2018-09-26 microRNA for inhibiting expression of Sirt1 gene of chicken, recombinant superficies plasmid thereof and LMH cell line

Country Status (1)

Country Link
CN (1) CN109161545B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020260327A1 (en) 2019-06-26 2020-12-30 F. Hoffmann-La Roche Ag Mammalian cell lines with sirt-1 gene knockout
CN113151355A (en) * 2021-04-01 2021-07-23 吉林省农业科学院 Dual-luciferase reporter gene vector of chicken STRN3 gene 3' UTR and construction method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1955301A (en) * 2006-10-19 2007-05-02 山东省农业科学院家禽研究所 Henpox virus universal transfer carrier, recombination henpox virus and its preparation method
CN102908621A (en) * 2011-08-02 2013-02-06 中国科学院上海生命科学研究院 New application of miRNAs for regulating insulin sensitivity as target

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1955301A (en) * 2006-10-19 2007-05-02 山东省农业科学院家禽研究所 Henpox virus universal transfer carrier, recombination henpox virus and its preparation method
CN102908621A (en) * 2011-08-02 2013-02-06 中国科学院上海生命科学研究院 New application of miRNAs for regulating insulin sensitivity as target

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
TSAI ET AL: "The role of microRNAs in modulating sirtuin 1 expression", 《JOURNAL OF CLINICAL GERONTOLOGY & GERIATRICS》 *
WANG ET AL: "Growth Hormone-Regulated mRNAs and miRNAs in Chicken Hepatocytes", 《PLOS ONE》 *
YAMAKUCHI ET AL: "miR-34a repression of SIRT1 regulates apoptosis", 《PNAS》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020260327A1 (en) 2019-06-26 2020-12-30 F. Hoffmann-La Roche Ag Mammalian cell lines with sirt-1 gene knockout
CN114026224A (en) * 2019-06-26 2022-02-08 豪夫迈·罗氏有限公司 Mammalian cell line with SIRT-1 gene knockout
JP2022538430A (en) * 2019-06-26 2022-09-02 エフ.ホフマン-ラ ロシュ アーゲー Mammalian cell line with SIRT-1 gene knockout
JP7450647B2 (en) 2019-06-26 2024-03-15 エフ. ホフマン-ラ ロシュ アーゲー Mammalian cell line with SIRT-1 gene knockout
CN114026224B (en) * 2019-06-26 2024-03-15 豪夫迈·罗氏有限公司 Mammalian cell lines with SIRT-1 gene knockouts
CN113151355A (en) * 2021-04-01 2021-07-23 吉林省农业科学院 Dual-luciferase reporter gene vector of chicken STRN3 gene 3' UTR and construction method and application thereof

Also Published As

Publication number Publication date
CN109161545B (en) 2021-07-27

Similar Documents

Publication Publication Date Title
US5972596A (en) Nucleic acid constructs containing HIV genes with mutated inhibitory/instability regions and methods of using same
KR20160023649A (en) Gene-therapy vectors for treating cardiomyopathy
CN102094037B (en) Reference internal type dual-luciferase reporter vector and application thereof
CN109161545B (en) microRNA for inhibiting expression of Sirt1 gene of chicken, recombinant superficies plasmid thereof and LMH cell line
CN106566832B (en) Short hairpin RNA (ribonucleic acid) aiming at NFAT3 gene target, recombinant vector and application
CN111534578A (en) Method for high-throughput screening of target gene of interaction between eukaryotic cells and pesticides
CN111718932A (en) Preparation method and application of novel gene editing animal bioreactor
CN112961832A (en) Cell strain and preparation method and application thereof
PT2385115E (en) Expression vector for producing protein derived from foreign gene in large quantity using animal cells, and use thereof
CN112245578B (en) COVID-19 virus preventive vaccine and preparation method thereof
CN111298129B (en) Metformin-mediated nucleic acid nanomaterial self-assembly method, nano preparation prepared by adopting method and application
CN111534544A (en) Method for high-throughput screening of eukaryotic cell and virus interaction target gene
KR101831121B1 (en) Nucleic acid structure containing a pyripyropene biosynthesis gene cluster and a marker gene
CN109316464B (en) Preparation comprising islet-like cell mass
CN109913484A (en) A kind of two-way expression carrier T with and its preparation method and application
CN110964748B (en) Carrier containing mitochondrion targeting sequence and construction method and application thereof
CN111793639B (en) Method for improving insecticidal activity of Bt by mixing with RNAi engineering bacteria
CN114085872A (en) Construction method and application of mouse model for expressing TVA
CN111549061A (en) Method for high-throughput screening of target genes of eukaryotic cells responding to extreme pH of environment
CN111534577A (en) Method for high-throughput screening of essential genes and growth inhibitory genes of eukaryotes
CN109336982B (en) Genetically modified stem cells and uses thereof
CN111549063A (en) Method for high-throughput screening of cell response environment extreme temperature target gene
US6623951B1 (en) HBV vectors and cells for producing the same
CN106715697A (en) Transformation method of sugar beet protoplasts by TALEN platform technology
JP2000014388A (en) Recombinant crp and its production

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant